Best Testosterone Supplement For Men Over 40 and 50: Testo Prime for Muscle Growth & Libido 2025 
Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced...
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities...
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T...
VitalHub announces SHREWD implementation with Winnipeg Regional Health Authority
TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to...
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
Additions of ProgenaMatrix® and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem’s commercial product portfolioPOMPANO BEACH, Fla., Nov....
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical...
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than...
Update on Clinical Milestone – CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed”...
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
NESS ZIONA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients...
Avextra Portugal Unveils Advanced Breeding Program to Develop Proprietary THC and CBD Cultivars, Establishing a Key IP Pillar
Avextra Portugal launches an innovative in-house breeding program to develop proprietary cannabis varieties with specific, consistent and reproducible cannabinoid and...
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease
- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in...
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each...
OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development
OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development Oxford, UK...
Hygrozyme® Celebrates 50 years of Innovation by Doubling Down on Agriculture and Cultivation Industries
DELTA, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pioneering the Future of Crop Cultivation To celebrate 50 years of...
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of the...
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the...
Press Release: Sequana Medical announces Extraordinary General Meeting of Shareholders on 20 December 2024
Sequana Medical announces Extraordinary General Meeting of Shareholders on 20 December 2024 Ghent, Belgium – 20 November 2024 – Sequana...
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes...
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
BioTech Company of the Year Cytek Biosciences has been named “Overall BioTech Company of the Year” in the fourth annual...
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
Improved operating performance by reducing net loss by $52.5 million; reported net loss of $4.3 million and $56.8 million for...